Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- Cardiovascular Systems Announces First Patient Enrolled In COMPLIANCE 360 Degree Clinical Trial
- Archimedes Pharma Announces Ground Breaking Phase III Data Showing NasalFent To Be Superior To The Standard Of Care For Breakthrough Cancer Pain
- Bristol-Myers Squibb And ZymoGenetics Present Final Phase 1b Results For PEG-Interferon Lambda In Hepatitis C
- Quality Candidates For National Boards Sought - Royal Pharmaceutical Society Of Great Britain
- Randomized Controlled Trial Shows Circumcision Does Not Reduce Male-To-Female HIV Transmission
- New Therapy Improves Chances Of Living Disease-free With Difficult-to-treat Childhood Cancer
- FDA Okays Diabetes Drug for First-Line Use, Adds Warning
- Mixed Results From Trials Of DHA In Alzheimer's Disease And Age-Related Cognitive Decline Emphasize The Need For Earlier Detection And Intervention
- Human Genome Sciences And Aegera Therapeutics Announce Initiation Of Clinical Trial Of Lead IAP Inhibitor HGS1029 In Advanced Lymphoid Tumors
- Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval To Proceed With Phase 3 Development Of OnaltaTM
Low Blood Glucose Levels Do Not Explain Excess Deaths In Accord Trial
Posted by: admin in Pharmacy Drugs on October 10th, 2009
Low blood glucose levels do not explain the excess deaths seen in the intensive control group of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, according to a report presented here today at the American Diabetes Association’s 69th Scientific Sessions.
“After the original ACCORD report showed an increased mortality risk in the intensive strategy group aiming to lower Centers for Disease Control and Prevention, provide support substudies.
Source
American Diabetes Association
View drug information on Glucagon.